1Global Burden of Disease Study 2013 Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 2015; 386: 743–800.
2Gaynes, BN, Warden, D, Trivedi, MH, Wisniewski, SR, Fava, M, Rush, AJ. What did STAR*D teach us? Results from a large-scale, practical, clinical trial for patients with depression. Psychiatr Serv 2009; 60: 1439–45.
3Rush, AJ, Trivedi, MH, Wisniewski, SR, Nierenberg, AA, Stewart, JW, Warden, D, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry 2006; 163: 1905–17.
4Caddy, C, Amit, BH, McCloud, TL, Rendell, JM, Furukawa, TA, McShane, R, et al. Ketamine and other glutamate receptor modulators for depression in adults. Cochrane Database Syst Rev 2015; 9: CD011612.
5Han, Y, Chen, J, Zou, D, Zheng, P, Li, Q, Wang, H, et al. Efficacy of ketamine in the rapid treatment of major depressive disorder: a meta-analysis of randomized, double-blind, placebo-controlled studies. Neuropsychiatr Dis Treat 2016; 12: 2859–67.
6Kishimoto, T, Chawla, JM, Hagi, K, Zarate, CA, Kane, JM, Bauwer, M, et al. Single-dose infusion ketamine and non-ketamine N-methyl-d-aspartate receptor antagonists for unipolar and bipolar depression: a meta-analysis of efficacy, safety and time trajectories. Psychol Med 2016; 46: 1459–72.
7Zhang, MWB, Hong, YX, Husain, SF, Harris, KM, Ho, RC. Analysis of print news media framing of ketamine treatment in the United States and Canada from 2000 to 2015. PLoS One 2017; 12: e0173202.
8Sanacora, G, Frye, MA, McDonald, W, Mathew, SJ, Turner, MS, Schatzberg, AF, et al. A consensus statement on the use of ketamine in the treatment of mood disorders. JAMA 2017; 74: 399–405.
10Loo, C. Can we confidently use ketamine as a clinical treatment for depression? Lancet Psychiatry 2018; 5: 11–12.
11Schatzberg, AF. A word to the wise about ketamine. Am J Psychiatry 2014; 171: 262–4.
12Singh, I, Morgan, C, Curran, V, Nutt, D, Schlag, A, McShane, R. Ketamine treatment for depression: opportunities for clinical innovation and ethical foresight. Lancet Psychiatry 2017; 4: 419–26.
13Diamond, PR, Farmery, AD, Atkinson, S, Haldar, J, Williams, N, Cowen, PJ, et al. Ketamine infusions for treatment resistant depression: a series of 28 patients treated weekly or twice weekly in an ECT clinic. J Psychopharmacol 2014; 28: 536–44.
15Berlim, MT, Turecki, G. Definition, assessment, and staging of treatment-resistant refractory major depression: a review of current concepts and methods. Can J Psychiatry 2007; 52: 46–54.
16Ionescu, DF, Swee, MB, Pavone, KJ, Taylor, N, Akeju, O, Baer, L, et al. Rapid and sustained reductions in current suicidal ideation following repeated doses of intravenous ketamine: secondary analysis of an open-label study. J Clin Psychiatry 2016; 77: e719–25.
17Apeldoorn, SY, de Boer, MK, Schoevers, RA. Reduction in suicidal ideation following repeated doses of intravenous ketamine? J Clin Psychiatry 2017; 78: e71.
18Sanacora, G, Heimer, H, Hartman, D, Mathew, SJ, Frye, M, Nemeroff, C, et al. Balancing the promise and risks of ketamine treatment for mood disorders. Neuropsychopharmacology 2016; 42: 1179–81.
19Rush, AJ, Gullion, CM, Basco, MR, Jarrett, RB, Trivedi, MH. The Inventory of Depressive Symptomatology (IDS): psychometric properties. Psychol Med 1996; 26: 477–86.
20Jakovljevic, M. Creative, person-centered and narrative psychopharmacotherapy or how to prevent and overcome treatment resistance in psychiatry. Psychiatr Danub 2015; 27: 291–301.
21Rasmussen, KG, Mueller, M, Kellner, CH, Knapp, RG, Petrides, G, et al. Patterns of psychotropic medication use among patients with severe depression referred for electroconvulsive therapy: data from the Consortium for Research on Electroconvulsive Therapy. J ECT 2006; 22: 116–23.